Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Evercore ISI Group Upgrades Ortho Clinical Diagnostic to Outperform, Announces $21 Price Target

Author: Benzinga Newsdesk | February 17, 2022 06:14am
Evercore ISI Group analyst Vijay Kumar upgrades Ortho Clinical Diagnostic (NASDAQ:OCDX) from In-Line to Outperform and announces $21 price target.

Posted In: OCDX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist